Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00250172 |
The purpose of this study is to measure a particular protein in the brain called the phosphodiesterase by using the imaging techniques of positron emission tomography (PET) and magnetic resonance imaging (MRI).
Condition | Intervention | Phase |
---|---|---|
Dosimetry Healthy |
Drug: [C-11](R)-rolipram |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram |
Estimated Enrollment: | 35 |
Study Start Date: | October 2005 |
Study Completion Date: | February 2009 |
Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Both basic and clinical studies have indicated that the 3', 5'-cyclic adenosine monophosphate (cAMP) system plays critical roles in several brain diseases, particularly in mood disorders and drug addiction. cAMP is synthesized from adenosine 5'-triphosphate (ATP) by adenylyl cyclase and metabolized by cyclic nucleotide phosphodiesterases (PDEs). Among components of the cAMP pathway, PDE4 appears to be critical for antidepressant effects.
4-[3-(cyclopentoxyl)-4-methoxyphenyl]-2-pyrrolidone (rolipram) is an inhibitor of PDE4. As a positron emission tomography (PET) brain imaging agent, rolipram has good properties such as high affinity of 1-2 nM and appropriate lipophilicity (Log P) of ~3. A rat study gave an estimation of low radiation absorbed doses of the active enantiomer (R)-[11C]rolipram. ciociWEge quality. Therefore, R-[11C]rolipram is a promising PET ligand.
However, radiation absorbed doses have not been estimated from human whole body imaging studies and a method to measure binding of (R)-[11C]rolipram in human brain has not been established.
The purposes of this protocol are to estimate radiation absorbed doses of (R)-[11C]rolipram by performing whole body imaging studies on healthy human subjects and also to establish an accurate method to measure PDE4 levels in brain by performing test retest brain imaging studies. The results of this overall study are required to apply this PET ligand in various neurological and psychiatric disorders in the future.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
All subjects must be healthy and aged 18-65 years.
EXCLUSION CRITERIA:
PART 1 (WHOLE BODY IMAGING STUDIES):
PART 2 (TEST RETEST BRAIN IMAGING STUDIES):
Study ID Numbers: | 060002, 06-M-0002 |
Study First Received: | November 5, 2005 |
Last Updated: | August 24, 2009 |
ClinicalTrials.gov Identifier: | NCT00250172 History of Changes |
Health Authority: | United States: Federal Government |
Dosimetry Pharmacokinetics Compartment Analysis |
Reproducibility Healthy Volunteer HV |
Rolipram Phosphodiesterase Inhibitors Psychotropic Drugs Healthy Antidepressive Agents |
Rolipram Phosphodiesterase Inhibitors Molecular Mechanisms of Pharmacological Action Therapeutic Uses Psychotropic Drugs |
Enzyme Inhibitors Central Nervous System Agents Pharmacologic Actions Antidepressive Agents |